Metastases to lymph nodes – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastases to lymph nodes – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases https://clinicaltrials.eu/trial/study-on-darolutamide-triptorelin-and-leuprorelin-acetate-for-patients-with-newly-diagnosed-prostate-cancer-and-pelvic-lymph-node-metastases/ Wed, 29 Apr 2026 14:58:15 +0000 https://clinicaltrials.eu/trial/study-on-darolutamide-triptorelin-and-leuprorelin-acetate-for-patients-with-newly-diagnosed-prostate-cancer-and-pelvic-lymph-node-metastases/ This clinical trial is focused on studying treatments for prostate cancer that has spread to the pelvic lymph nodes. The study will evaluate the effects of adding a medication called darolutamide to standard treatments, which include androgen deprivation therapy (ADT) and radiation therapy. Darolutamide is a type of medication known as an antiandrogen, which helps block male hormones that can promote cancer growth. The trial will also involve the use of other hormone therapies, such as triptorelin, leuprorelin acetate, and degarelix, which are given by injection to help reduce hormone levels in the body.

The purpose of this study is to see how well the combination of these treatments works in preventing the cancer from getting worse. Participants will be randomly assigned to receive either darolutamide or a placebo, along with the standard hormone and radiation therapies. The study will last for up to 24 months, during which time participants will receive regular check-ups and monitoring to assess their health and the effectiveness of the treatment.

Throughout the study, participants will undergo various tests and scans, such as MRI and CT scans, to monitor the cancer’s response to treatment. The study aims to improve understanding of how these treatments can help manage prostate cancer and improve outcomes for patients. Participants will be closely monitored for any side effects or changes in their condition, and their quality of life will also be assessed during the trial period.

]]> Study on the Use of Iron Oxide Nanoparticles in MRI to Detect Lymph Node Metastasis in Patients with Newly Diagnosed Rectal Cancer https://clinicaltrials.eu/trial/study-on-the-use-of-iron-oxide-nanoparticles-in-mri-to-detect-lymph-node-metastasis-in-patients-with-newly-diagnosed-rectal-cancer/ Wed, 29 Apr 2026 14:28:05 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-iron-oxide-nanoparticles-in-mri-to-detect-lymph-node-metastasis-in-patients-with-newly-diagnosed-rectal-cancer/ This clinical trial focuses on studying rectal cancer and its spread to nearby lymph nodes, known as mesorectal lymph node metastases. The study will use a special type of Magnetic Resonance Imaging (MRI) that involves a contrast agent called Ferumoxtran-10, which contains tiny particles of iron oxide. This contrast agent helps to create clearer images of the lymph nodes during the MRI scan.

The purpose of the study is to determine how accurately this enhanced MRI can identify the stage of cancer in the lymph nodes compared to the traditional method of examining tissue samples after surgery. Participants in the study will undergo an MRI scan with the Ferumoxtran-10 contrast agent, as well as a standard MRI without the contrast. These imaging results will be compared to the findings from the tissue samples taken during surgery.

The study will involve patients who have been newly diagnosed with rectal cancer and are scheduled for surgery or a short course of radiotherapy before surgery. The trial aims to improve the understanding of how well the enhanced MRI can detect cancer spread to the lymph nodes, which could potentially lead to better treatment planning for patients in the future.

]]>